S&P 500   4,443.84 (-0.26%)
DOW   34,923.68 (+0.36%)
QQQ   369.57 (-1.01%)
AAPL   145.11 (-1.23%)
MSFT   293.69 (-1.89%)
FB   351.11 (-0.52%)
GOOGL   2,822.70 (-0.76%)
TSLA   794.34 (+2.58%)
AMZN   3,375.84 (-1.45%)
NVDA   215.36 (-2.47%)
BABA   148.28 (+2.21%)
NIO   36.32 (+2.66%)
CGC   14.66 (+5.39%)
GE   106.00 (+2.12%)
MU   75.15 (+1.49%)
AMD   107.20 (+1.32%)
T   27.60 (+1.73%)
F   14.27 (+3.56%)
ACB   6.35 (+6.72%)
DIS   179.18 (+1.81%)
PFE   43.83 (-0.25%)
BA   226.19 (+2.17%)
BAC   43.40 (+2.99%)
S&P 500   4,443.84 (-0.26%)
DOW   34,923.68 (+0.36%)
QQQ   369.57 (-1.01%)
AAPL   145.11 (-1.23%)
MSFT   293.69 (-1.89%)
FB   351.11 (-0.52%)
GOOGL   2,822.70 (-0.76%)
TSLA   794.34 (+2.58%)
AMZN   3,375.84 (-1.45%)
NVDA   215.36 (-2.47%)
BABA   148.28 (+2.21%)
NIO   36.32 (+2.66%)
CGC   14.66 (+5.39%)
GE   106.00 (+2.12%)
MU   75.15 (+1.49%)
AMD   107.20 (+1.32%)
T   27.60 (+1.73%)
F   14.27 (+3.56%)
ACB   6.35 (+6.72%)
DIS   179.18 (+1.81%)
PFE   43.83 (-0.25%)
BA   226.19 (+2.17%)
BAC   43.40 (+2.99%)
S&P 500   4,443.84 (-0.26%)
DOW   34,923.68 (+0.36%)
QQQ   369.57 (-1.01%)
AAPL   145.11 (-1.23%)
MSFT   293.69 (-1.89%)
FB   351.11 (-0.52%)
GOOGL   2,822.70 (-0.76%)
TSLA   794.34 (+2.58%)
AMZN   3,375.84 (-1.45%)
NVDA   215.36 (-2.47%)
BABA   148.28 (+2.21%)
NIO   36.32 (+2.66%)
CGC   14.66 (+5.39%)
GE   106.00 (+2.12%)
MU   75.15 (+1.49%)
AMD   107.20 (+1.32%)
T   27.60 (+1.73%)
F   14.27 (+3.56%)
ACB   6.35 (+6.72%)
DIS   179.18 (+1.81%)
PFE   43.83 (-0.25%)
BA   226.19 (+2.17%)
BAC   43.40 (+2.99%)
S&P 500   4,443.84 (-0.26%)
DOW   34,923.68 (+0.36%)
QQQ   369.57 (-1.01%)
AAPL   145.11 (-1.23%)
MSFT   293.69 (-1.89%)
FB   351.11 (-0.52%)
GOOGL   2,822.70 (-0.76%)
TSLA   794.34 (+2.58%)
AMZN   3,375.84 (-1.45%)
NVDA   215.36 (-2.47%)
BABA   148.28 (+2.21%)
NIO   36.32 (+2.66%)
CGC   14.66 (+5.39%)
GE   106.00 (+2.12%)
MU   75.15 (+1.49%)
AMD   107.20 (+1.32%)
T   27.60 (+1.73%)
F   14.27 (+3.56%)
ACB   6.35 (+6.72%)
DIS   179.18 (+1.81%)
PFE   43.83 (-0.25%)
BA   226.19 (+2.17%)
BAC   43.40 (+2.99%)
OTCMKTS:HKMPF

Hikma Pharmaceuticals Stock Forecast, Price & News

$34.25
-0.05 (-0.15 %)
(As of 09/16/2021)
Add
Compare
Today's Range
$34.25
$34.25
50-Day Range
$34.25
$37.70
52-Week Range
$30.15
$37.70
Volume100 shs
Average Volume1,700 shs
Market Capitalization$8.30 billion
P/E Ratio20.03
Dividend YieldN/A
Beta0.41
30 days | 90 days | 365 days | Advanced Chart
Receive HKMPF News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Hikma Pharmaceuticals logo

About Hikma Pharmaceuticals

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.20 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Hikma Pharmaceuticals (OTCMKTS:HKMPF) Frequently Asked Questions

Is Hikma Pharmaceuticals a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Hikma Pharmaceuticals stock.
View analyst ratings for Hikma Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Hikma Pharmaceuticals?

Wall Street analysts have given Hikma Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Hikma Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Hikma Pharmaceuticals?

Hikma Pharmaceuticals saw a decline in short interest in August. As of August 31st, there was short interest totaling 77,600 shares, a decline of 72.7% from the August 15th total of 284,000 shares. Based on an average daily trading volume, of 200 shares, the days-to-cover ratio is currently 388.0 days.
View Hikma Pharmaceuticals' Short Interest
.

How has Hikma Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Hikma Pharmaceuticals' stock was trading at $24.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HKMPF stock has increased by 39.8% and is now trading at $34.25.
View which stocks have been most impacted by COVID-19
.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals declared a Semi-Annual dividend on Friday, August 6th. Stockholders of record on Friday, August 20th will be given a dividend of $0.18 per share on Monday, September 20th. The ex-dividend date of this dividend is Thursday, August 19th.
View Hikma Pharmaceuticals' dividend history
.

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the following people:
  • Sigurdur Oli Olafsson, Chief Executive Officer & Director
  • Henriette Nielsen, Executive Vice President-Business Operations
  • Khalid Walid Hosni Nabilsi, Chief Financial Officer
  • Shahin Fesharaki, Chief Scientific Officer
  • Mazen Samih Taleb Darwazah, Executive Vice Chairman & President-MENA Region

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPF."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HKMPF stock can currently be purchased for approximately $34.25.

How much money does Hikma Pharmaceuticals make?

Hikma Pharmaceuticals has a market capitalization of $8.30 billion and generates $2.34 billion in revenue each year. The company earns $431 million in net income (profit) each year or $1.71 on an earnings per share basis.

How many employees does Hikma Pharmaceuticals have?

Hikma Pharmaceuticals employs 8,681 workers across the globe.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is www.hikma.com.

Where are Hikma Pharmaceuticals' headquarters?

Hikma Pharmaceuticals is headquartered at 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The company can be reached via phone at 442073992760 or via email at [email protected].


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.